H. Worth (Fuerth, Germany), W. Pohl (Grimmenstein, Austria)
Safety of beclomethasone HFA (HFA BDP) pMDI compared with beclomethasone CFC pMDI (CFC BDP) over 12 weeks
J. Joshi, K. Jagannath, D. Gothi, Balamurugan, C. J. Po, C. Bowker, A. Sule, J. Gogtay, S. Purandare (Mumbai, India; , ; Portsmouth, United Kingdom)
|  |
The small airway inflammation of asthmatic patients who have used dry powder type inhaled steroid for moderate-long term evaluated by induced sputum and the efficacy of HFA-BDP (QVAR) inhalation
H. Ohbayashi (Mizunami City, Japan)
| |
Budesonide HFA pMDI is pharmacokinetically and clinically comparable with budesonide CFC pMDI in healthy volunteers, and in adults and children with asthma
D. Singh, A. Tutuncu, I. Lohr, M. Carlholm, T. Polanowski (Manchester, United Kingdom; Muttenz, Switzerland; Lund, Sweden)
| |
Inhaled corticosteroids in treatment of patients with intermittent bronchial asthma: yes or no?
D. D. Djordjevic, I. J. Stankovic, M. H. Rancic, L. M. Ristic (Nis, Serbia And Montenegro)
| |
A single blinded randomised trial to compare the efficacy and safety of once daily budesonide (400μg) administered by turbuhaler with beclomethasone dipropionate (400μg) given twice daily through a metered-dose inhaler in patients with mild to
O. M. Ige, O. M. Sogaolu (Ibadan, Nigeria)
| |
Randomized clinical trial (RCT) comparing formoterol vs. salbutamol plus ipratropium bromide in the treatment of acute asthma exacerbation (AE) at emergency room (ER)
I. Solarte, M. Bermudez, P. Hidalgo, J. M. Sanchez, L. Y. Sanchez (Bogota, Colombia)
| |
The in vitro fine particle dose with Symbicort Rapihaler pMDI is similar using either NebuChamber or AeroChamber Plus valved holding chamber spacer devices
F. Chambers, E. Berg, M. Brown, J. O. Svensson (Loughborough, United Kingdom; Lund, Sweden)
| |
Acute asthma: large volume spacers are the best
S. Bhatti, A. Shah, E. Osakwe, H. Bradman, P. Sherwood (London, United Kingdom)
| |
Effect of decrease allergen exposition in preventing the bronchial asthma
G. A. Breskovska, M. G. Gavrilovski, G. I. Ljube, B. G. Gerovski, S. P. Stojkovski (Skopje, Fyrom)
| |
The influence of hypobaric training on the clinical course of bronchial asthma
T. M. Sooronbaev, E. M. Mirrakhimov (Bishkek, Kyrgyzstan)
| |
Allergic bronchopulmonary aspergillosis - therapeutical role of bronchoalveolar lavage
A. N. Parau, D. V. Todea, M. V. Vasile (Cluj-Napoca, Romania)
| |
Use of alternative therapies in patients with asthma and COPD: is there any difference?
S. Bavbek, E. Gullu, E. Sen, O. Keskin, S. Saryal, Z. Misirligil (Ankara, Turkey)
| |
The effect of salt room treatment on bronchial hyperresponsiveness in asthmatics: a randomised controlled trial
J. Hedman, T. Hugg, T. Haahtela (Lappeenranta, Finland)
| |
Bronchial hyperreactivity in patients with bronchial asthma and its correction during the high altitude adaptation
T. M. Sooronbaev (Bishkek, Kyrgyzstan)
| |
Patient perception of the effect of breathing exercises for asthma
C. A. Slader, S. Z. Bosnic-Anticevich, C. R. Jenkins, C. L. Armour, H. K. Reddel (Camperdown, Sydney, Australia)
| |
The impact of systemic corticosteroids on respiratory muscle function in severe asthma
J. Chlumsky (Prague, Czech Republic)
| |
Salmeterol response is not affected by beta2-adrenergic receptor genotype in patients with persistent asthma
P. M. Dorinsky, S. W. Yancey, L. D. Edwards, L. B. Sutton (Research Triangle Park, United States Of America)
| |
Ambulatory 24 hours pH monitoring in a pulmonary department; retrospective results of 289 patients
T. Tran, W. Van den Berg, J. Janssen (Nijmegen, Netherlands)
| |